Sildenafil Repurposed: A New Hope for Mitochondrial Disease
A groundbreaking study published in *Cell* reveals a promising new therapeutic avenue for Leigh syndrome, a severe and untreatable mitochondrial disease. Researchers employed patient-derived pluripotent stem cell models in both 2D and 3D formats to conduct a drug-repurposing screen. This innovative approach identified sildenafil, a phosphodiesterase-5 (PDE5) inhibitor, as a potent candidate. The drug demonstrated significant efficacy, not only extending lifespan in mammalian disease models but also leading to measurable clinical improvement in six individuals with Leigh syndrome, offering a potential breakthrough for a condition with no current cure.
Study Significance: This research directly impacts the field of microbial pathogenesis and host-pathogen interactions, as mitochondrial function is a critical battleground in many infectious diseases. For microbiologists, the study validates advanced screening platforms using patient-derived cells, a methodology applicable for discovering host-targeted therapies against viral or bacterial pathogens that disrupt cellular energetics. It underscores a strategic shift towards repurposing existing drugs, which can accelerate the translation of findings from bench to bedside for urgent medical needs.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
